CN108602779A - 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法 - Google Patents

制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法 Download PDF

Info

Publication number
CN108602779A
CN108602779A CN201680081965.5A CN201680081965A CN108602779A CN 108602779 A CN108602779 A CN 108602779A CN 201680081965 A CN201680081965 A CN 201680081965A CN 108602779 A CN108602779 A CN 108602779A
Authority
CN
China
Prior art keywords
compound
slurry
mixture
optionally
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680081965.5A
Other languages
English (en)
Chinese (zh)
Inventor
C.贝茨
D.P.里德
毛建民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Priority to CN202210565751.2A priority Critical patent/CN114874149A/zh
Publication of CN108602779A publication Critical patent/CN108602779A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201680081965.5A 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法 Pending CN108602779A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210565751.2A CN114874149A (zh) 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562268758P 2015-12-17 2015-12-17
US62/268758 2015-12-17
PCT/US2016/067161 WO2017106639A1 (en) 2015-12-17 2016-12-16 Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210565751.2A Division CN114874149A (zh) 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法

Publications (1)

Publication Number Publication Date
CN108602779A true CN108602779A (zh) 2018-09-28

Family

ID=59057623

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680081965.5A Pending CN108602779A (zh) 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法
CN202210565751.2A Pending CN114874149A (zh) 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210565751.2A Pending CN114874149A (zh) 2015-12-17 2016-12-16 制备取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺的方法

Country Status (16)

Country Link
US (4) US9834519B2 (enExample)
EP (2) EP4015508A1 (enExample)
JP (2) JP6940504B2 (enExample)
KR (1) KR20180085814A (enExample)
CN (2) CN108602779A (enExample)
AU (2) AU2016369520B2 (enExample)
BR (1) BR112018012325A2 (enExample)
CA (1) CA3006077A1 (enExample)
EA (1) EA201891431A1 (enExample)
HK (1) HK1255014A1 (enExample)
IL (1) IL259557A (enExample)
MX (2) MX385672B (enExample)
NZ (1) NZ742785A (enExample)
SG (1) SG11201804601TA (enExample)
TW (1) TWI748972B (enExample)
WO (1) WO2017106639A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4015508A1 (en) * 2015-12-17 2022-06-22 ArQule, Inc. Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
AU2016369523B2 (en) 2015-12-17 2021-12-23 Arqule, Inc. Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
CN110669015A (zh) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 一种fgfr抑制剂的制备方法
US10878412B2 (en) * 2019-05-13 2020-12-29 Truist Bank In-line verification of transactions
WO2022053708A1 (en) 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028281A1 (en) * 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
CN101115749A (zh) * 2004-12-17 2008-01-30 安姆根有限公司 氨基嘧啶化合物和使用方法
WO2008142720A2 (en) * 2007-05-17 2008-11-27 Dac Srl Quinazolin-oxime derivatives as hsp90 inhibitors
CN102325755B (zh) * 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
CA2710051C (en) 2006-12-29 2017-05-16 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
SG11201607772WA (en) * 2014-03-31 2016-10-28 Debiopharm Int Sa Fgfr fusions
EP4015508A1 (en) * 2015-12-17 2022-06-22 ArQule, Inc. Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
AU2016369523B2 (en) 2015-12-17 2021-12-23 Arqule, Inc. Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028281A1 (en) * 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
CN101115749A (zh) * 2004-12-17 2008-01-30 安姆根有限公司 氨基嘧啶化合物和使用方法
WO2008142720A2 (en) * 2007-05-17 2008-11-27 Dac Srl Quinazolin-oxime derivatives as hsp90 inhibitors
CN102325755B (zh) * 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王香善 等: "微波辐射下2-氨基苯并[h]喹唑啉衍生物的合成", 《有机化学》 *

Also Published As

Publication number Publication date
MX2018007415A (es) 2018-11-09
KR20180085814A (ko) 2018-07-27
BR112018012325A2 (pt) 2018-12-04
CN114874149A (zh) 2022-08-09
MX2020012771A (es) 2022-10-04
IL259557A (en) 2018-07-31
JP6940504B2 (ja) 2021-09-29
US20190241527A1 (en) 2019-08-08
EP3390368A4 (en) 2019-07-03
JP2021191782A (ja) 2021-12-16
US10766868B2 (en) 2020-09-08
AU2021202610B2 (en) 2022-06-02
AU2016369520A1 (en) 2018-06-07
CA3006077A1 (en) 2017-06-22
EA201891431A1 (ru) 2018-11-30
EP3390368A1 (en) 2018-10-24
SG11201804601TA (en) 2018-07-30
US20170174637A1 (en) 2017-06-22
US11279679B2 (en) 2022-03-22
JP2018537495A (ja) 2018-12-20
TW201733992A (zh) 2017-10-01
TWI748972B (zh) 2021-12-11
WO2017106639A1 (en) 2017-06-22
AU2016369520B2 (en) 2021-02-18
US9834519B2 (en) 2017-12-05
US20180065937A1 (en) 2018-03-08
NZ742785A (en) 2023-06-30
US10093632B2 (en) 2018-10-09
US20200102276A1 (en) 2020-04-02
HK1255014A1 (zh) 2019-08-02
EP4015508A1 (en) 2022-06-22
AU2021202610A1 (en) 2021-05-27
MX385672B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
US11279679B2 (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
JP6779793B2 (ja) リンパ腫を治療するためのｅｚｈ２阻害剤
CN109311852B (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶
US20140357622A1 (en) Crystalline forms of sodium 4--2-methoxybenzoate
CN102834097B (zh) 纯化的吡咯并喹啉基-吡咯烷-2,5-二酮组合物和用于制备且使用其的方法
TW202204345A (zh) 改善mRNA剪接之化合物
US20230056497A1 (en) CD206 Modulators Their Use and Methods for Preparation
US20200002293A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
WO2023024545A1 (zh) Fgfr4抑制剂、组合物及其在药物制备中的用途
HK40079039A (en) Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
CN113891749A (zh) 喹啉衍生物及其用于治疗癌症的用途
US20200039967A1 (en) Novel forms of afatinib dimaleate
CN115894474A (zh) Rad51抑制剂化合物的晶型及其应用
EA042753B1 (ru) Способы получения полиморфа дигидрохлорида замещенного 5,6-дигидро-6-фенилбензо[f]изохинолин-2-амина
JP2011515493A (ja) 抗原受容体により誘導されるＮＦ−κＢの活性化の阻害剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination